MOUNTAIN VIEW, Calif., Feb. 25, 2013 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq : ALXA ) announced today its corporate presentation will be webcast live at three upcoming investor conferences. A live webcast of each presentation may be accessed from the Investor Relations section of the Alexza Pharmaceuticals website at www.alexza.com. The conferences and presentation times include:
- Cowen & Company 33rd Annual Health Care Conference in Boston, MA on Tuesday, March 5, 2013 at 11:20 am ET
- 25th Annual ROTH Conference in Dana Point, CA on Monday, March 18, 2013 at 5:30 pm ET
- Future Leaders in the Biotech Industry Conference in New York, NY on Friday, April 5, 2013 at 10:30 am ET
A replay of each webcast will be available approximately 24 hours following the completion of the respective presentation and will be available for 14 days following the each presentation, on the Investor Relations section of the company's website.
About Alexza Pharmaceuticals, Inc.
Alexza Pharmaceuticals is focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions, including agitation, acute repetitive seizures and insomnia. Alexza's products are based on the Staccato® system, a hand-held inhaler that is designed to deliver a drug aerosol to the deep lung, providing rapid systemic delivery and therapeutic onset with ease and convenience for patients.
ADASUVE® (Staccato loxapine) is Alexza's first approved product, which was approved by the U.S. Food and Drug Administration in December 2012 and by the European Medicines Agency in February 2013. Grupo Ferrer Internacional, S.A. is Alexza's commercial partner for ADASUVE in Europe, Latin America, Russia and the Commonwealth of Independent States countries. The commercial launch of ADASUVE is planned for the third quarter 2013 in the U.S. and Europe.
ADASUVE® and Staccato® are registered trademarks of Alexza Pharmaceuticals, Inc.
Safe Harbor Statement
The anticipated presentation will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs, including the ability for Alexza and Ferrer to effectively and profitably commercialize ADASUVE, the adequacy of the Company's capital to support the Company's operations, and the Company's ability to raise additional funds and the potential terms of such potential financings. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2011 and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
SOURCE Alexza Pharmaceuticals, Inc.